Jan 3

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

Dec 23, 2024

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

Oct 13, 2024

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

Oct 13, 2024

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

Oct 9, 2024

US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter

Aug 24, 2024

FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter

Aug 8, 2024

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

Aug 8, 2024

FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata

Aug 5, 2024

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

Jul 4, 2024

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

Jun 20, 2024

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

Jun 19, 2024

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

Jun 18, 2024

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

May 31, 2024

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

May 16, 2024

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

Apr 30, 2024

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

Apr 20, 2024

FDA Drug Approvals | 2024 | iPharmaCenter

Mar 20, 2024

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

Mar 16, 2024

FDA Gives Green Light to First Medication for Individuals with Liver Scarring Stemming from Fatty Liver Condition | iPharmaCenter

Dec 21, 2023

2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

Nov 30, 2023

FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter

Nov 18, 2023

Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter

Nov 18, 2023

Project Orbis News | Updates | Truqap approved in the US

Nov 12, 2023

FDA-Approved Chronic Weight Management Drug Zepbound, rival to Wegovy

Oct 18, 2023

UCB potential multi-billion blockbuster Bimzelx approved for plaque psoriasis | FDA | iPharmaCenter

Aug 22, 2023

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

Aug 14, 2023

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

Aug 5, 2023

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

Jul 17, 2023

FDA Approved RSV treatments | iPharmaCneter

Jun 29, 2023

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

Jun 28, 2023

FDA Approved diabetic treatments | 2023 |

Jun 27, 2023

FDA Approved Myasthenia gravis treatments | News | Updates | iPharmaCenter

Jun 23, 2023

US FDA approved drugs for Duchenne Muscular Dystrophy | Elevidys | Viltepso | iPharmaCenter

Jun 21, 2023

FDA News and Updates | US Pharma News | iPharmaCenter

Feb 7, 2023

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

Nov 23, 2022

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

Sep 11, 2022

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

Aug 19, 2022

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

Jun 25, 2022

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

May 30, 2022

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

May 29, 2022

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

Dec 23, 2021

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

Dec 23, 2021

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Apr 9, 2021

Gilead’s Trodelvy approved for triple-negative breast cancer in US

Mar 13, 2021

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

Sep 7, 2020

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC